Introduction
NSCLC, pneumonitis, dyspnea, cancer, cough
PNEUMONITIS, CANCER, SMALL CELL LUNG CANCER, NSCLC, OPACITIES, ADVERSE DRUG EVENTS
The non–small cell lung cancer (NSCLC) treatment landscape shifted in 2015 when the FDA approved the first immune checkpoint inhibitors (ICI) for treatment of NSCLC (ICIs downregulate pathways that suppress T-cell activation to enhance antitumor immune responses in patients with cancer, but this upshift in immune-mediated activity can also result in “off-target” immune-related adverse drug events, including pneumonitis (Clinical and radiographic characteristics of ICI-related pneumonitis include cough and dyspnea as well as ground glass opacities on chest CT scans (Given the limited, and sometimes conflicting estimates in the current literature, this study was conducted to address two objectives: (i) to describe the occurrence of treatment-associated pneumonitis (TAP) in patients with NSCLC in the real-world data (RWD) setting compared with randomized clinical trials (RCT; treated with either ICI or chemotherapy); and (ii) to describe potential risk factors of patients diagnosed with TAP.